

SIMRIS GROUP

INTERIM REPORT

JANUARY–MARCH 2023

THE PERIOD IN BRIEF - GROUP

SEK thousands	Jan-Mar 2023	Jan-Mar 2022	Δ	Full year 2022
Net revenue	488	3 206	-85%	4 080
EBITDA	-5 999	-3 420	-75%	-18 005
EBIT / Operating result	-9 595	-4 144	-132%	-24 657
Result before tax	-10 485	-4 007	-162%	-25 766
Cash flow from operating activities	-6 632	-3 291	-102%	-18 188
Cash at the end of the period	1 849	942	96%	3 994

Note: numbers in brackets are comparable figures from the previous year.

Q1, JANUARY-MARCH 2023

- Net revenue decreased by 85% to SEK 488k (3 206k) following a planned 3-month shutdown in production to upgrade the Hammenhög production facility.
- Personnel and other external costs increased by 79% to SEK -6 291k (-3 517k) due to increased investments in capability and infrastructure, including Cyano Biotech.
- Comparing Personnel and other external costs on a like-for-like basis (i.e., excluding Cyano Biotech), costs increased by 34% vs Q1 2022 of which a large proportion were one-off costs.
- In line with limited sales, EBITDA declined by 75% to SEK -5 999k (-3 420k).
- EBIT/ Operating result declined by 132% to SEK -9 595k (-4 144k) driven by depreciation following the acquisition of Cyano Biotech.

KEY EVENTS ANNOUNCED IN Q1

- Simris announced the launch of its newly formulated Omega-3 product in Sweden on 10th January.
- On 24th January, Simris confirmed an increase in the flexible funding facility from The Brand Laboratories (TBL), a company associated with the Chairman, by €0,5m, taking the full value of the facility to €1,5m.
- On 31st January, Simris announced it was proposing to change the name of the company to Simris Group AB.
- Simris published its Year End Report on 15th February.
- On 28th February, Simris announced it had signed a strategic collaboration agreement with Lonza, who as Simris' CDMO hold the exclusive rights to promote its ADC payload platform to drug development companies.

- An EGM was held on 6th March; Shareholders resolved to (1) change the name of the business to Simris Group; (2) approve an increase in the funding facility from The Brand Laboratories; (3) amend the Articles of Association.
- On 13th March Simris confirmed that the name of the company had been officially changed to Simris Group AB.
- On 27th March, Simris announced that following the restart of bioreactors at its Hammenhög facility in January it had experienced record growth rates.

KEY EVENTS AFTER Q1

- On 17th April, Simris published its Annual Report for 2022 and announced its Annual General Meeting would be moved from 15th to 29th May.
- On 21st April, the Board of Simris announced it had resolved to accept an offer to extend its flexible loan facility with TBL by a further €150k.
- On 28th April, Simris announced broader distribution of its Omega-3 products with launch on www.amazon.com in USA and a listing in two Swedish pharmacy chains.
- On 2nd May, Simris announced it had received its largest single B2B order for fucoxanthin-rich biomass, worth up to 4,0MSEK.
- On 5th May, the Board accepted an offer from the former owners of Cyano Biotech to extend the due date on the second payment for the acquisition, from 25th August to 2nd October.
- On 5th May, the Board accepted an offer from TBL to extend the due date for payment of its flexible loan facility, from 25th August to 2nd October.

CEO UPDATE

I joined the company almost one year ago, with a clear objective to position the company for robust sales growth. We began with a focus on building new revenue platforms, and these investments are already delivering results. First came the transformational acquisition of Cyano Biotech, moving us firmly into the more lucrative biopharma space. Next came the collaboration agreement we secured with Lonza, which not only gave 3rd party validation to our patented ADC platform but also brings us much closer to securing high value licensing contracts with drug developers. Time and resource investments made at our Hammenhög facility have yielded astounding results: biomass is now growing at twice our best historical rates, and other process improvements from our R&D now show highest-ever cell density and much-improved biosecurity. Taken together, this has culminated in the recent receipt of our first B2B order for the year, which is also the largest order we have ever received. The newly formulated Simris Omega-3 products have been launched on amazon.com in the USA as well as our own website in Sweden and will shortly be online at the two largest pharmacy chains in Sweden. On top of all of this, we have strengthened the teams in both Berlin and Hammenhög to build upon this momentum. Not surprisingly, as I reflect on the progress Simris has made since the start of the year, I am more optimistic than ever about the future.



Julian Read
CEO

FUNDING:

The question I receive most frequently from investors regards the funding of the business. I therefore feel it is appropriate to address this question directly to you, our Shareholders, in this report. Simris currently has cash for operations through to the end of Q3. Before this date, the Board of Directors intend to secure additional investment to fund the longer-term growth of the business in line with our corporate objectives. In our previous quarterly report, we confirmed that the business had cash for operations through to the end of Q2. This improvement of our runway stems from four areas:

1. Sales revenues from Omega-3, fucoxanthin-rich biomass and cyanobacterial laboratory standards are strengthening our short-term cashflow;
2. The former owners of Cyano Biotech have offered to extend the original due date for the second (final) acquisition payment of €1m from 25 August 2023 to 2 October 2023;
3. The Brand Laboratories FZ has also offered to extend the repayment date on their flexible loan facility from 25 August 2023 to 2 October 2023, for better alignment;
4. The Brand Laboratories FZ has also extended the total loan facility amount by €150k to €1,65m, should it be needed.

Based upon the substantial progress the business has made over the past 12-months, by any measure Simris is in a stronger position than it has ever been. In light of this, the Board are currently evaluating a broader raft of options for future funding than have been previously available. A decision as to which route(s) will be taken will be communicated shortly.

BIOPHARMACEUTICALS:

The market for Antibody Drug Conjugates (ADC's) is growing rapidly in scale and revenue. In June 2022 there were over 400 ADC drugs in development, of which more than 200 were in the clinical stage. As for revenue, Daiichi Sankyo alone expects global revenue for its Enhertu® drug to exceed \$1.5B in 2023. In March of this year, Pfizer offered \$43B to acquire Seagen, whose late-stage development programs and expertise in ADC's strongly complement Pfizer's Oncology portfolio.

Post-merger, Pfizer will hold six of the fourteen FDA-approved ADC's as well as a pipeline of clinical-stage ADC candidates. The ADC space is on fire, as the full potential of precision cancer therapeutics unfolds. In this context it is immediately apparent that the collaboration agreement that Simris signed with Lonza earlier this year is transformative in unlocking value.

As one of the world's largest pharmaceutical Contract Development and Manufacturing Organisations (CDMOs), Lonza already produces the majority of commercially available ADCs for the major drug developers. Now, as Simris' CDMO partner, Lonza holds the exclusive rights to promote Simris' patented ADC payload technology to its customers. Simply put, Lonza bridges the gap between Simris and the drug developer. As an example of how this collaboration can be immediately beneficial, Simris has been invited to present to Lonza customers during a three-day Conjugation Summit later this month.

A few months back, in March, I attended a World ADC conference in London where the majority of companies working in the ADC field gathered to promote their various technologies. I was taken aback by the diverse interest shown in our patented payload technology, resulting in a number of discussions which are now underway with drug developers internationally. At about the same time we engaged a specialist external consultancy (with considerable experience in pharmaceutical licensing deals relating to ADCs), to advise us on an optimised license model and to put likely numbers to each stage. The output of this work confirmed our model. ADC license agreements have a typical structure:

1. An *upfront licence fee* to reserve the exclusive right for the drug developer to develop their ADC with our payload towards a *specific target* on one or more cancer cell lines. On average these fees have been 5% of the total value of the license agreement; a typical upfront license fee can be several millions of dollars.
2. *Funded research collaboration* fees during pre-clinical development, whereby Simris would be paid to perform research and development to modify its payload for optimal performance as part of the developing ADC medicine and to supply the drug developer with toxic payloads.
3. *Milestone Payments*, made during the development of the product,

* ADC = Antibody Drug Conjugate: targeted cancer therapy and improved patient life quality

are paid upon achieving key milestones e.g., at the end of the pre-clinical stage, at the end of each stage of clinical trials, and again when the medicine gains regulatory clearance. Average milestone payments are each single-digit millions of dollars in the early clinical stage and increase to double-digit millions of dollars during the later stages of clinical trial and regulatory approval.

4. *Royalty fees* from commercial sale of the ADC medicine carrying one of our payloads. From disclosed FY2022 financial statements sales of ADC drugs were more than \$7bn. The market is expected to be grow to over \$20bn by 2030 making it apparent that revenue from royalties can be significant.

Our research on deals done goes back to 2018; since then, the average total value of a single ADC license deal (with all milestone payments and royalties included) has been \$300m. Whilst it is true that only a few drug candidates have made it all the way through to commercial sale, even just the upfront licensing fees and early milestone payments from a single license agreement for our ADC payload platform would represent meaningful revenue for Simris and attract further significant interest in our technology. Encouragingly, 6 of the 15 FDA-approved ADCs are based on cyanobacteria toxins, which is exactly the space we are in.

As previously communicated, we have already welcomed one new scientist to the Berlin team in February. Our second new team member joined at the beginning of May, thereby expanding our capabilities in conjugation chemistry and payload production. We plan to strengthen the team further before the end of the year, on the Business Development / Sales side, to drive progress commercially.

NUTRACEUTICALS:

SWEDEN: We are off to a very encouraging start! Direct to Consumer (D2C) Q1 sales of our newly launched Omega-3 products in Sweden are twice the sales we achieved for all of the products in the previous range during Q1 of 2022. On top of this, all the reviews we have received for the new product have been 5-star with favourable comments about how easy the new capsules are to swallow, how nice the storage jar is, and the merits of the refill pack concept that minimises wasteful packaging. Listing in the main pharmacy chains is a central part of our distribution strategy for Sweden. A 2022 IPSOS consumer study showed that more than 60% of shoppers expect to find food supplements in pharmacies, and I am pleased to report that we have secured listings for our new Omega-3 products with the two largest pharmacy chains in Sweden; Kronans Apotek began selling Simris Omega-3 products from May 1st, and the first shipment to Apoteket will be made shortly to enable sale beginning of June.

USA: Following a successful marketing trial that began on amazon.com in the USA in mid-March, Simris Omega-3 products are now available on the world's largest retail website. In just a short time Simris has made it onto the first page when searching for algal Omega-3 products. Based on favourable results to date we will continue to invest in first page visibility whilst simultaneously driving trial and successful reviews. Once

a clear revenue pattern is established, the broader plan is to add other innovative microalgae and cyanobacteria inspired supplement products, as well as to launch into key European markets during H2.

ENHANCED BIOSECURITY & QUALITY:

As mentioned in the previous Quarterly Report, in Q4 of last year (when electricity prices are highest and growth rates are lowest) we emptied our entire photobioreactor production system to perform a deep clean and to make a number of upgrades recommended by our R&D Team. The results have surpassed our expectations. The smaller bioreactors were restarted in January, and new growth rates are more than three times historical record rates. Likewise, scale-up from the smaller to the larger reactors has gone smoothly and, thanks to the accelerated growth rates, harvesting began at the end of April, 6-weeks ahead of schedule. Overall, with these higher growth rates, we expect to produce twice as much biomass as before. This is an outstanding result from the Hammenhög team, and for the first time sets the foundation for the facility to be a profit centre for the Group.

FOOD INGREDIENTS FOR B2B:

We received our first order of the year for fucoxanthin-rich biomass early in May. The order, which has a total value of up to 4.0MSEK, comes from an existing customer that requires the highest possible quality of the biomass. This is the single largest order we have received to date, with deliveries required from June to August. The first 60% of the order is confirmed, with the remaining 40% to be confirmed by the end of Q2. Based upon the latest production forecast for Hammenhög, we expect to have capacity to make to make additional sales before the end of 2023.

SUMMARY:

After 12-months of targeted action across multiple business areas, Simris Group is in its strongest position ever. We have completed the successful and accretive acquisition of Cyano Biotech, we have secured the collaboration agreement with Lonza, we have lifted the capacity and efficiency of the Hammenhög facility by a factor of 2x, we have reformulated the Simris Omega 3 range to be globally compliant, we have launched it on amazon.com and made it freely available in Sweden, and we have kicked off the B2B business with our largest order ever of approximately 4,0MSEK. Most importantly, we are sitting on an exceptional, patent protected, technology platform within one of the hottest biotech areas, namely ADC medicines, and believe that a licensing deal is achievable within the next 9-12 months.

This is a completely new Simris: new Board, new management, new objective, new business model, new biopharma positioning. Simris is finally ready to deliver on its potential and I am looking forward to the years ahead.



The Simris logo is written in a stylized, cursive, teal-colored font.

OVERVIEW

NET REVENUE AND PROFIT

Net revenue during the first quarter amounted to SEK 488k (3 206k). The year-on-year decline in sales for the quarter is explained by lower B2B biomass sales versus the same period in 2022. Due to the planned pause in production to upgrade the production system and improve biosecurity. The smaller photobioreactors restarted in January whilst upgrades on the larger systems continued. By the end of the quarter biomass was growing at record rates allowing harvesting to begin at the end of April, some 6-weeks ahead of schedule. The company received its single largest order for biomass to date for up to 4,0MSEK. Demand for biomass from B2B customers remains and with current growth rates the business will be able to supply further orders during the year.

Following the launch of the new Omega-3 supplement Direct to Consumers (D2C) in Sweden in January, Food Supplement sales were more than double those of Q1, 2022. The products were launched for D2C sales on amazon.com in the USA at the end of March. Furthermore, the two largest pharmacy chains in Sweden (Kronans Apoteket and Apoteket), will list Simris Omega-3 at their online stores from May and June respectively.

The EBIT/ Operating result for the first quarter declined by 132% to SEK -9 595k (-4 114k). The lower EBIT in the first quarter can be explained by a combination of lower revenues, investment in the launch of the new Omega-3 products, the upgrade of the Hammenhög production facility and depreciation associated with the acquisition of Cyano Biotech.

The change in inventory during the first quarter amounted to SEK -31k (-2 434k) and the total inventory value amounted to SEK 2 226k (914k) at the end of the period.

FIXED ASSETS

The total value of the Group's fixed assets amounted to SEK 177 393k (22 681k) at the end of the period.

Tangible Assets at the end of the period were SEK 22 110k (22 632k). Investments for the quarter amounted to SEK 545k.

Intangible Assets at the end of the period were SEK 155 276k (0). This is based upon investments associated with the acquisition of Cyano Biotech.

Depreciation of fixed assets was made according to relevant accounting standards, with SEK 3 596k (724k) during the first quarter. Fixed assets are depreciated over 5-10 years for most fixtures and fittings, and over the remaining lifetime for patents - 15 years for the patents and technology gained through the Cyano Biotech acquisition), and up to 40 years for the buildings.

LIQUIDITY AND FINANCING

Cash flow from operating activities amounted to SEK -6 632k (-3 291k) during the first quarter. Cash flow amounted to SEK -2 145k (-19k) for the first quarter. At the end of the period, cash and cash equivalents

amounted to SEK 1 849k (942k). The total liabilities at the end of the period amounted to SEK 169 846k (13 936k).

The debt on the balance sheet following the acquisition of Cyano Biotech is €8m and takes account of the maximum earn-out from the ADC platform. For the earn-out to be paid out at the maximum value, Simris would have sales revenue of €80m from the ADC platform over the next 15 years. Such revenue would be expected to be at a high profit margin.

On the August 25, 2022, The Brand Laboratories FZ (TBL), a company associated with Simris Chairman, Steven Schapera, providing the business with a flexible funding facility of up to €1.0m to be drawn down as and when required. The loan was to be paid back within twelve months and accumulates interest at 1.0% per month. On 24th January Simris announced that TBL offered to increase the funding facility by a further €0,5m on the same terms as the original €1,0m facility. On 21st April the Board accepted an offer from TBL to extend the loan facility by a further €150k. At the end of Q1 €1,15m of the loan facility had been called upon.

On 5th May the Board accepted an offer from the former owners of Cyano Biotech to extend the due date on the second payment for the acquisition, from 25th August to 2nd October.

At the same time the Board accepted an offer from TBL to extend the due date for payment of its flexible loan facility, from 25th August to 2nd October.

The Board's assessment is that existing funding will cover the company's working capital requirements until at least the end of Q3 2023.

EQUITY

The Group's equity amounted to SEK 13 795k (13 902k) at the end of the period. The solidity was 7.5 percent, compared with 12.0 percent on December 31, 2022.

SHARES AND THE OWNERS

The total number of shares on issue amounts to 180 302 520 B-shares at the end of the period.

As of 31st March 2023, Simris Group AB had 6 605 shareholders (6 595), of which the ten largest had 29 percent of the share capital and the votes. Simris Group's B shares have been listed on Nasdaq First North Growth Market since April 22, 2016. During the last quarter, the highest price paid for the share was SEK 0.678 and the lowest was SEK 0.252. The last paid price at the end of the period was SEK 0.517, which gave a market capitalization value of approximately SEK 93m. A total of 26.7 million shares were traded during the quarter.

OPTION PROGRAM

At the end of the period, Simris Group had five outstanding Option programs.

Series 2019/1 consists of 43 438 options and was issued to employees of the company in May 2019. The options have a term of five years and for each option, 1.45 B shares can be subscribed for at a price of 4.44 SEK per share. Exercise of outstanding options corresponds to a dilution of the share capital by less than 0.1 percent.



Series 2021/2024:S consists of 2 000 000 options and was issued to the Board in May 2021. The options have a term of three years, and each option gives the right to subscription of 1.34 B shares at a subscription price of SEK 1.42 per share. Utilization of outstanding options corresponds to a dilution of the share capital by 1.5 percent.

Series 2021/2024:L consists of 1 820 000 options and was issued to senior executives and employees in the company in May 2021. The options have a term of three years, and each option gives the right to subscription of 1.34 B shares at a subscription price of SEK 1.42 per share. Utilization of outstanding options corresponds to a dilution of the share capital by 1.4 percent.

Series 2022/1 consists of 1 750 000 options and was issued to the CEO of the company in May 2022. The options have a term of three years, and each option gives the right to subscription of 1.34 B shares at a subscription price of SEK 0.91 per share. Utilization of outstanding options corresponds to a dilution of the share capital by 1.3 percent.

Series 2022/2 consists of 1 750 000 options and was issued to the CEO of the company in May 2022. The options have a term of two years, and each option gives the right to subscription of 1.34 B shares at a subscription price of SEK 1.42 per share. Utilization of outstanding options corresponds to a dilution of the share capital by 1.3 percent.

STAFF AND ORGANIZATION

During the quarter, we had one employee leave the business. We secured the support of experienced temporary staff throughout Q4 and into Q1 to support the launch of our new Omega-3 product and the upgrades to the Hammenhög site. The average number of employees amounted to 9 (8) during the first quarter.

PARENT COMPANY

Simris Group AB is the parent company. Net revenue for the Parent Company during the quarter amounted to SEK 505k (2 931k). EBIT/ Operating result amounted to SEK -5 023k (-3 986k) for the quarter. Result before tax amounted to SEK -5 770k (-4 171k) for the quarter.

TRANSACTIONS WITH RELATED PARTIES

By the end of quarter Simris had drawn down €1.15m of the €1.65m flexible funding facility provided by The Brand Laboratories FZ, a company associated with Simris Chairman, Steven Schapera. The loan

had a setup fee of 2.5%, accumulates interest at 1.0% per month and is to be paid back by 2nd October 2023.

In addition to normal Board work during the first quarter, Board Directors performed consulting services for the company, of which Brand Laboratories FZ LLC (a company associated with Steven Schapera), invoiced SEK 197k, Robert Quandt SEK 27k, Magnus Högström SEK 14k and Frank Puccio SEK 18k.

ACCOUNTING PRINCIPLES

Simris Group prepares its accounts in accordance with the Annual Accounts Act and the Accounting Boards general advice 2012:1(K3). Information on accounting principles in general is provided in the Financial Statement for 2022.

AUDIT

This report has not been reviewed by Simris Group's auditor.

RISKS AND UNCERTAINTIES

Simris Group's operations, financial position and earnings can be affected by a number of risks and uncertainties. These are described in Simris Group's Financial Statement for 2022, at www.simrisgroup.com.

Simris Group is in the start-up phase and still lacks sufficient earnings to cover the costs of the business through sales revenue. Simris Group is reliant upon planned additional external funding in 2023 to be able to continue its operations, as well as to make the final payment for the acquisition of Cyano Biotech, repay loans, and implement growth plans. Whilst the Board is confident that the business is in its strongest position ever, and that it will be able to raise the funds required for future investment and growth, there is always a risk that new capital cannot be acquired when needed, or that new capital cannot be obtained on satisfactory terms, or that the procured capital is not sufficient to finance the operations in accordance with established development plans and objectives.

Increased energy prices are an indirect impact resulting from the current situation in Ukraine. Other than additional cost, there is no direct impact on Simris Groups operations.

The Board of Directors and the CEO assure that the report provides a fair overview of the group's operations, position and results.

Steven Schapera
Chairman

Magnus Högström
Board Director

Julian Read
CEO

Robert Quandt
Board Director

Frank Puccio
Board Director



INCOME STATEMENT - GROUP

SEK thousands	Jan-Mar 2023	Jan-Mar 2022	Full year 2022
Net revenue	488	3 206	4 080
Change of finished goods and work in progress	-47	-2 526	-3 676
Activated work for own account	0	0	0
Other operating income	151	6	646
Raw materials and consumables	-300	-589	-1 146
Other external expenses	-4 006	-2 098	-10 865
Personnel expenses	-2 285	-1 419	-7 044
Depreciation and amortization	-3 596	-724	-6 652
Operating result / EBIT	-9 595	-4 144	-24 657
Financial net	-890	137	-1 109
Result before tax	-10 485	-4 007	-25 766
Tax	846	-25	1 344
Result for the period	-9 639	-4 032	-24 422
(Attributable to the parent company's shareholders)	-9 639	-4 032	-24 422

BALANCE SHEET - GROUP

SEK thousands	31 Mar 2023	31 Mar 2022	31 Dec 2022
Assets			
Fixed Assets			
Intangible assets	155 276	0	155 899
Tangible assets	22 110	22 632	22 417
Financial assets	7	49	0
Total Fixed Assets	177 393	22 681	178 316
Current Assets			
Inventory	2 226	914	2 257
Other receivables	2 173	3 301	1 145
Cash and bank balances	1 849	942	3 994
Total Current Assets	6 248	5 157	7 396
Total Assets	183 641	27 838	185 712
Equity and Liabilities			
Equity	13 795	13 902	23 034
Provisions			
Deferred tax	47 110	91	47 331
Liabilities			
Long-term Liabilities	92 613	1 580	91 480
Short-term Liabilities	30 123	12 265	23 867
Total Liabilities	169 846	13 936	162 678
Total Equity and Liabilities	183 641	27 838	185 712

CASH FLOW ANALYSIS - GROUP

SEK thousands	Jan-Mar 2023	Jan-Mar 2022	Full year 2022
Cash flow from operating activities before changes in working capital	-6 535	-3 570	-17 961
Cash flow from working capital	-97	279	-227
Cash flow from operating activities	-6 632	-3 291	-18 188
Cash flow from investing activities	-545	0	-22 382
Cash flow from financing activities	5 032	3 272	43 603
Cash flow for the period	-2 145	-19	3 033
Cash and cash equivalents opening balance	3 994	961	961
Cash and cash equivalents closing balance	1 849	942	3 994

CHANGE IN EQUITY - GROUP

SEK thousands	Jan-Mar 2023	Jan-Mar 2022	Full year 2022
Opening balance	23 034	18 221	18 221
Issue (including issue costs)	0	0	28 022
Stock option program	0	0	105
Translation differences	400	-287	1 108
Result for the period	-9 639	-4 032	-24 422
Closing balance	13 795	13 902	23 034

KEY FIGURES - GROUP

SEK thousands	Jan-Mar 2023	Jan-Mar 2022	Full year 2022
Net revenue (kSEK)	488	3 206	4 080
EBIT (kSEK)	-9 595	-4 144	-24 657
Cash at the end of the period (kSEK)	1 849	942	3 994
Equity (kSEK)	13 795	13 902	23 034
Earnings per share (SEK)	neg.	neg.	neg.
Earnings per share after full dilution (SEK)	neg.	neg.	neg.
Equity per share (SEK)	0,08	0,18	0,13
Equity per share after full dilution (SEK)	0,08	0,18	0,13
Number of shares, average	180 302 520	78 547 046	142 397 290
Number of shares, end of period	180 302 520	78 547 046	180 302 520
Number of shares after full dilution*	180 302 520	78 547 046	180 302 520
Solidity (%)	7,5	49,9	12,0
Balance sheet total (kSEK)	183 641	27 838	185 712
Cash liquidity (%)	13	35	22
Average number of employees	9	7	8

*Simris Alg has five outstanding warrant programs. Dilution effects have not been taken into account for any of the programs for any of the above period, as the average price of Simris Alg's share in each period has been less than the subscription price in the programs. If full subscription takes place within the framework of the option programs, the number of shares will increase by 9871785.

KEY FIGURE DEFINITIONS

Balance sheet total – The sum of all assets in the balance sheet or sum of all liabilities and equity.

Equity per share – Adjusted equity (equity and untaxed reserves less deferred tax) divided by the number of shares at the end of the period.

Equity per share after full dilution – Adjusted equity (equity and untaxed reserves less deferred tax) divided by the number shares at the end of the period taking into account after conversion and adjusted for effect of share-based payments.

Cash liquidity – Current assets excluding inventories and work in

progress as a percentage of current liabilities.

Net revenue – Operating main income, invoiced costs, side income and income corrections.

Earnings per share – Earnings for the period divided by the number of shares after the end of the period.

Earnings per share after full dilution – Earnings for the period divided by number shares after the end of the period, taking into account after conversion and adjusted for effect of share-based payments.

EBIT/ Operating result – Result before financial expenses and tax.

Solidity – Adjusted equity at the end of the period as a percentage of total asset.

INCOME STATEMENT – PARENT COMPANY

SEK thousands	Jan-Mar 2023	Jan-Mar 2022	Full year 2022
Net revenue	505	2 931	3 060
Change of finished goods and work in progress	-278	-2 207	-2 357
Activated work for own account	0	0	0
Other operating income	0	6	258
Raw materials and consumables	-213	-590	-1 016
Other external expenses	-2 845	-1 989	-9 751
Personnel expenses	-1 462	-1 419	-6 093
Depreciation and amortization	-730	-718	-2 872
Operating result / EBIT	-5 023	-3 986	-18 771
Financial net	-747	-185	-1 108
Result before tax	-5 770	-4 171	-19 879
Tax	-3	-3	-13
Result for the period	-5 773	-4 174	-19 892

BALANCE SHEET – PARENT COMPANY

SEK thousands	31 Mar 2023	31 Mar 2022	31 Dec 2022
Assets			
Fixed Assets			
Tangible assets	20 374	22 632	20 558
Financial assets	117 899	9	113 887
Total Fixed Assets	138 273	22 641	134 445
Current Assets			
Inventory	438	640	739
Receivables from group companies	626	0	1 117
Other receivables	1 182	3 176	808
Cash and bank balances	1 338	658	3 490
Total Current Assets	3 584	4 474	6 154
Total Assets	141 857	27 115	140 599
Equity and Liabilities			
Equity	19 884	13 249	25 657
Provisions			
Deferred tax	104	91	101
Liabilities			
Long-term Liabilities	92 613	1 580	91 480
Short-term Liabilities	29 256	12 195	23 361
Total Liabilities	121 973	13 866	114 942
Total Equity and Liabilities	141 857	27 115	140 599



FINANCIAL CALENDAR:

Interim Report Q1, 2023: 08 May 2023
Annual General Meeting: 29 May 2023
Interim Report Q2, 2023: 09 August 2023
Interim Report Q3, 2023: 08 November 2023
Year-end Report 2023: 14 February 2024

FOR MORE INFORMATION:

Julian Read, CEO
Phone: +46 (0)767 888 212
Email: IR@simris.com

This information is information that Simris Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on 08 May 2023.

Simris Groups shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664. Organisation number 556841-9187. Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: info@amudova.se.

© SIMRIS GROUP AB • Pioneering algae biotech since 2011
+46(0)414-44 50 50 • info@simris.com • www.simrisgroup.com
Herrestadsvägen 24A, 276 50 Hammenhög, Sweden

Simris